Skip to content
    AVIR
    Earnings call· Jun 2026(Q2 FY26)

    Atea Pharmaceuticals Q2 FY26 earnings call AVIR

    Aug 12, 2026 Source

    Executive summary

    Atea Pharmaceuticals Q2 FY26 — Positive Phase 3 C-Beyond Results and Pipeline Advancement

    Atea Pharmaceuticals reported positive Phase 3 C-Beyond trial results for its hepatitis C regimen, BAM-RZR, demonstrating non-inferiority to the standard of care and reinforcing its potential best-in-class profile for a complex patient population. The company is advancing its C-Forward trial and a novel hepatitis E program, while maintaining a solid financial position. Management believes BAM-RZR is uniquely positioned to expand the HCV market by addressing treatment barriers and capturing untreated patients, targeting a mid-2028 launch.

    Highlights

    5

    • Positive top-line results from the Phase 3 C-Beyond trial for BAM-RZR, meeting primary and secondary endpoints with 93.9% SVR rate, demonstrating non-inferiority to standard of care.

    • C-Forward Phase 3 trial fully enrolled with over 880 patients, on track for top-line results in early Q1 2027.

    • Initiated first-in-human Phase 1 clinical trial for AT587, a potential first-in-class direct-acting antiviral for chronic Hepatitis E.

    • Strong financial position with $219.5 million in cash and marketable securities as of June 30, 2026, with cash runway anticipated through 2027.

    • Anticipated peak annual U.S. net revenue potential in excess of $700 million for BAM-RZR, with market expansion potential up to $2.5 billion annually.

    Concerns

    2

    • The HCV market is often perceived as declining by Wall Street, despite a widening gap between new infections and treated patients, posing a challenge for market perception.

    • Current SVR rates with approved therapies can fall as low as 74% among people who injected drugs, highlighting ongoing treatment adherence and access barriers in the real world.

    Guidance & targets

    6
    CategoryTargetConfidence
    C-Forward Phase 3 Top-line Results
    early Q1 2027
    high materiality
    High
    Cash Runway
    through 2027
    medium materiality
    High
    NDA Submission (BAM-RZR)
    second quarter of 2027
    high materiality
    High
    Hepatitis E Program Proof of Concept
    2027
    medium materiality
    Medium
    BAM-RZR Launch
    mid-2028
    high materiality
    High
    BAM-RZR Peak Annual U.S. Net Revenue Potential
    in excess of $700 million
    high materiality
    High

    Operational metrics

    22
    Cash and marketable securities balance
    $219.5 million
    Q2 FY26

    Company remains in a solid financial position.

    R&D expenses
    increasedcompared to prior year
    H1 FY26
    G&A expenses
    decreasedcompared to prior year
    H1 FY26
    C-Beyond SVR rate (BAM-RZR)
    93.9%
    Week 24

    Achieved in the primary endpoint MITT population.

    C-Beyond SVR rate (Eclusa/Sofvel)
    94.8%
    Week 24

    Achieved in the primary endpoint MITT population.

    C-Beyond SVR rate (BAM-RZR, non-cirrhotic)
    93.5%
    8 weeks of treatment
    C-Beyond SVR rate (Sofvel, non-cirrhotic)
    94.6%
    12 weeks of treatment
    C-Beyond SVR rate (BAM-RZR, compensated cirrhotic)
    95.4%
    12 weeks of treatment

    Both arms achieved this rate.

    C-Beyond SVR rate (Sofvel, compensated cirrhotic)
    95.4%
    12 weeks of treatment

    Both arms achieved this rate.

    C-Beyond non-inferiority margin
    5%
    Trial design

    Trial powered with this margin.

    C-Beyond trial power
    90%
    Trial design
    HCV patients taking concomitant medications
    80 to 90%
    Current

    A key differentiator for BAM-RZR's drug-drug interaction profile.

    HCV infected population
    4 milliongrowing towards
    Current

    Represents an expanding addressable market.

    New infected patients treated annually
    50%
    2025

    Only around 50% of new infected patients were treated in 2025.

    Untreated new infections
    75,000
    last year

    On top of the already large prevalent pool of patients.

    US net sales (HCV market)
    $1.3 billion
    2025

    Representing 50% of global net sales.

    Global net sales (HCV market)
    $2.6 billion
    2025
    HCV market expansion potential
    $2.5 billion
    annually

    BAM-RZR uniquely positioned to expand the market.

    High-volume DAA prescribers likely to prescribe BAM-RZR
    76%
    Current

    Based on market research.

    HCV prescribers writing 80% of DAA prescriptions
    7,800
    Current

    Market is highly concentrated.

    Target sales force size
    75 to 100
    Pre-launch

    To reach the vast majority of the market.

    Historical SVR rates (people who injected drugs)
    74%as low as
    Past studies

    Illustrates real-world challenges in HCV treatment.

    Industry KPIs

    4
    MetricValueDetails
    Peak sales guidance$700 millionUSD
    Pricing policy impactInflation Reduction Act, Medicare Part D, 340B
    Pipeline clinical milestones2Phase 3 trials
    Clinical trial efficacy safety data93.9% SVR rate (BAM-RZR) vs 94.8% (Sofvel)%

    Risks & headwinds

    3
    Perception of declining HCV marketCurrent

    Wall Street often looks at revenue trends for approved HCD therapies and concludes that this is a declining market.

    Mitigation: Company highlights growing infected population (moving towards 4 million in US) and widening gap between infections and treatment as an expanding addressable market, positioning BAM-RZR to capture untreated patients and grow the market.

    Real-world adherence and discontinuation in HCV treatmentCurrent

    SDR rates with approved therapies can fall below the rates reported 10 years ago in the original pivotal studies, including rates as low as 74% among people who injected drugs.

    Mitigation: BAM-RZR's profile (short 8-week duration, protease inhibitor-free, low DDI) is designed to address these barriers and improve treatment completion.

    Impact of pricing reforms (Inflation Reduction Act, Medicare Part D, 340B)Ongoing

    Inflation Reduction Act has had an effect on manufacturers with higher Medicare patient percentages. Could affect Medicaid discounts. Proposed 340B changes could be favorable by shifting to rebate mechanism.

    Mitigation: Management notes that pricing differential between US and EU for HCV drugs is not as dramatic as for other pharmaceuticals, and some manufacturers are already cutting direct deals with state Medicaid agencies.

    What to watch in Q3 FY26

    5

    C-Forward Phase 3 Top-line Results

    early Q1 2027
    CurrentFully enrolled (880+ patients)
    TargetPositive top-line results

    Why it matters

    Confirmatory efficacy data across broader genotypes is crucial for a broad pangenotypic label and global regulatory package.

    We remain on track to report top-line results in early Q1, 2027.

    Q&A highlights

    5

    How will the new MOA be incorporated into the label, and what steps are needed to fully implement the test-and-treat model with the blister pack given payer requirements for refills?

    Management stated that the full dataset on the new MOA will be shared with the FDA early next year and presented at scientific meetings. For test-and-treat, while blister packs are for convenience, the quantity given depends on payer allowances in specific states. Physicians implementing test-and-treat have seen success and are excited about BAM-RZR's profile due to fewer DDI and shorter course.

    “We anticipate to share with the FDA early next year when we'll have the full dataset. So it's a little bit early for me to discuss about it, but obviously we will present at scientific meetings and share with the FDA with the impact that we believe that this supplemental important MOA for them and totally unique.”

    asked by Andy Shea · answered by Jean-Pierre Sommadossi

    2 min read6 chapters

    Detailed Narrative

    01

    C-Beyond Phase 3 Trial Success

    Atea announced positive top-line results from its C-Beyond Phase 3 trial for BAM-RZR in North America, demonstrating statistical non-inferiority to the current standard of care, Eclusa. The trial met both primary and secondary endpoints, achieving a 93.9% SVR rate for BAM-RZR compared to 94.8% for Eclusa at week 24 in the MITT population, within the pre-specified 5% non-inferiority margin. This success is significant as it was conducted in a real-world patient population with high comorbidities and adherence challenges.

    02

    C-Forward Phase 3 Trial Progress

    The second Phase 3 trial, C-Forward, being conducted outside North America to enable a broad pangenotypic label, is fully enrolled with over 880 patients. Top-line results are expected in early Q1 2027. This trial is enriched for genotypes 1B, 3, 4, 5, and 6, and will provide confirmatory efficacy data across a broader range of genotypes, strengthening the regulatory package for BAM-RZR.

    03

    AT587 Hepatitis E Program Advancement

    Atea initiated its first-in-human Phase 1 clinical trial for AT587, a potential first-in-class direct-acting antiviral for chronic hepatitis E, a serious disease with no approved treatment. The study is being conducted in healthy volunteers to evaluate safety, tolerability, and pharmacokinetics, with the first cohort already completed. This program represents a meaningful pipeline beyond hepatitis C.

    04

    HCV Market Opportunity and Commercial Strategy

    Management highlighted a widely misunderstood dynamic in the HCV market, where early diagnosed infections continue to outpace treated patients, leading to a growing addressable market of nearly 4 million people in the U.S. They believe BAM-RZR's profile, with its short 8-week duration for non-cirrhotic patients, protease inhibitor-free composition, and low drug-drug interaction potential, is optimal for the emerging "test and treat" model of care.

    05

    Commercial Readiness and Market Potential

    Atea is advancing commercial readiness activities, including manufacturing and packaging. Market research indicates strong uptake potential, with 76% of high-volume DAA prescribers extremely likely to prescribe BAM-RZR. The company projects peak annual U.S. net revenue potential in excess of $700 million, contributing to a potential market expansion of up to $2.5 billion annually in the U.S.

    06

    Financial Position and Discipline

    The company reported a solid financial position with $219.5 million in cash and marketable securities as of June 30, 2026. They anticipate a cash runway through 2027, with spending primarily focused on advancing the Hepatitis C program and pre-launch activities. R&D expenses increased in the first six months of 2026 due to the Phase 3 HCV program and HEV preclinical/clinical startup, while G&A decreased due to lower salaries and stock-based compensation.

    AI-generated summary of the company’s earnings call. Not investment advice.